- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Beyond the OCM: How Are Commercial Payers & Employers Delivering Value-Based Cancer Care? Part 4
Experts from The US Oncology Network discuss the future of value-based cancer care, and what practices can do as the Oncology Care Model expires.
In this webinar from The American Journal of Managed Care®'s Oncology Value Coalition, experts from The US Oncology Network discussed the future of value-based cancer care.
Despite many successes, the Oncology Care Model (OCM) is set to expire in July 2022, with no replacement on the horizon. That doesn't mean the lessons of the OCM will be forgotten, but continuing the quality care efforts will be difficult. How will practices continue team-based care, patient navigation, and other enhanced services?
The speakers were:
- Rhonda Henschel, senior director of payer solutions, The US Oncology Network
- Ben Jones, vice president of government relations and public policy
McKesson Specialty Provider Organization, The US Oncology Network - Stuart Staggs, senior director of strategic programs, The US Oncology Network
- Lalan Wilfong, MD,vice president of payer relations and practice transformation, The US Oncology Network
In segment 4, they discussed moving forward with value-based cancer care after the OCM.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD
May 17th 2025Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.
Read More
